AIMS: Cross-sectional evidence indicates that abdominal adiposity, hypertension, dyslipidaemia and glycaemia are associated with reduced metabolic clearance rate of insulin (MCRI). Little is known about the progression of MCRI and whether components of metabolic syndrome are associated with the change in MCRI. In this study, we examined the association between components of metabolic syndrome and the 5-year change of MCRI. METHODS: At baseline and 5-year follow-up, we measured fasting plasma triglycerides (TG), high-density lipoprotein (HDL) cholesterol, blood pressure (BP), waist circumference (WC) and fasting blood glucose (FBG) in 784 non-diabetic participants in the Insulin Resistance Atherosclerosis Study. MCRI, insulin sensitivity (SI ) and acute insulin response (AIR) were determined from frequently sampled intravenous glucose tolerance tests. RESULTS: We observed a 29% decline of MCRI at follow-up. TG, systolic BP and WC at baseline were inversely associated with a decline of MCRI regression models adjusted for age, sex, ethnicity, smoking, alcohol consumption, energy expenditure, family history of diabetes, BMI, SI and AIR [β = -0.057 (95% confidence interval, CI: -0.11, -0.0084) for TG, β = -0.0019 (95% CI: -0.0035, -0.00023) for systolic BP and β = -0.0084 (95% CI: -0.013, -0.0039) for WC; all p < 0.05]. Higher HDL cholesterol at baseline was associated with an increase in MCRI [multivariable-adjusted β = 0.0029 (95% CI: 0.0010, 0.0048), p = 0.002]. FBG at baseline was not associated with MCRI at follow-up [multivariable-adjusted β = 0.0014 (95% CI: -0.0026, 0.0029)]. CONCLUSIONS: MCRI declined progressively over 5 years in a non-diabetic cohort. Components of metabolic syndrome at baseline were associated with a significant change in MCRI.
AIMS: Cross-sectional evidence indicates that abdominal adiposity, hypertension, dyslipidaemia and glycaemia are associated with reduced metabolic clearance rate of insulin (MCRI). Little is known about the progression of MCRI and whether components of metabolic syndrome are associated with the change in MCRI. In this study, we examined the association between components of metabolic syndrome and the 5-year change of MCRI. METHODS: At baseline and 5-year follow-up, we measured fasting plasma triglycerides (TG), high-density lipoprotein (HDL) cholesterol, blood pressure (BP), waist circumference (WC) and fasting blood glucose (FBG) in 784 non-diabeticparticipants in the Insulin Resistance Atherosclerosis Study. MCRI, insulin sensitivity (SI ) and acute insulin response (AIR) were determined from frequently sampled intravenous glucose tolerance tests. RESULTS: We observed a 29% decline of MCRI at follow-up. TG, systolic BP and WC at baseline were inversely associated with a decline of MCRI regression models adjusted for age, sex, ethnicity, smoking, alcohol consumption, energy expenditure, family history of diabetes, BMI, SI and AIR [β = -0.057 (95% confidence interval, CI: -0.11, -0.0084) for TG, β = -0.0019 (95% CI: -0.0035, -0.00023) for systolic BP and β = -0.0084 (95% CI: -0.013, -0.0039) for WC; all p < 0.05]. Higher HDL cholesterol at baseline was associated with an increase in MCRI [multivariable-adjusted β = 0.0029 (95% CI: 0.0010, 0.0048), p = 0.002]. FBG at baseline was not associated with MCRI at follow-up [multivariable-adjusted β = 0.0014 (95% CI: -0.0026, 0.0029)]. CONCLUSIONS: MCRI declined progressively over 5 years in a non-diabetic cohort. Components of metabolic syndrome at baseline were associated with a significant change in MCRI.
Authors: S R Wiesenthal; H Sandhu; R H McCall; V Tchipashvili; H Yoshii; K Polonsky; Z Q Shi; G F Lewis; A Mari; A Giacca Journal: Diabetes Date: 1999-04 Impact factor: 9.461
Authors: B V Howard; E J Mayer-Davis; D Goff; D J Zaccaro; A Laws; D C Robbins; M F Saad; J Selby; R F Hamman; R M Krauss; S M Haffner Journal: Metabolism Date: 1998-10 Impact factor: 8.694
Authors: L E Wagenknecht; E J Mayer; M Rewers; S Haffner; J Selby; G M Borok; L Henkin; G Howard; P J Savage; M F Saad Journal: Ann Epidemiol Date: 1995-11 Impact factor: 3.797
Authors: C Christine Lee; Steve M Watkins; Carlos Lorenzo; Lynne E Wagenknecht; Dora Il'yasova; Yii-Der I Chen; Steven M Haffner; Anthony J Hanley Journal: Diabetes Care Date: 2016-02-19 Impact factor: 19.112
Authors: Malcolm A Leissring; Carlos M González-Casimiro; Beatriz Merino; Caitlin N Suire; Germán Perdomo Journal: Int J Mol Sci Date: 2021-02-24 Impact factor: 5.923
Authors: Nora E Straznicky; Mariee T Grima; Carolina I Sari; Elisabeth A Lambert; Sarah E Phillips; Nina Eikelis; Daisuke Kobayashi; Dagmara Hering; Justin A Mariani; John B Dixon; Paul J Nestel; Sofie Karapanagiotidis; Markus P Schlaich; Gavin W Lambert Journal: Cardiovasc Diabetol Date: 2015-08-22 Impact factor: 9.951
Authors: Artak Labadzhyan; Jinrui Cui; Miklós Péterfy; Xiuqing Guo; Yii-Der I Chen; Willa A Hsueh; Jerome I Rotter; Mark O Goodarzi Journal: PLoS One Date: 2016-11-15 Impact factor: 3.240
Authors: Zhila Semnani-Azad; Luke W Johnston; Christine Lee; Ravi Retnakaran; Philip W Connelly; Stewart B Harris; Bernard Zinman; Anthony J Hanley Journal: BMJ Open Diabetes Res Care Date: 2019-11-24